Join SITC for Advances in Cancer Immunotherapy™ (ACI) programs Sept. 14 in Pittsburgh, PA and Sept. 16 in New Haven, CT. Learn clinical applications of immunotherapy for disease states with FDA-approved treatments and much more!
SITC 2017 is the premier destination for scientific exchange, education and networking in the cancer immunotherapy field. Reserve your spot today!
"Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma."
SITC is excited to announce the 29 early career scientists who will comprise the 2018 Cohort of the SITC Sparkathon, which will enlist young investigators to identify and solve hurdles facing the field of cancer immunotherapy.
SITC connectED is the new adaptive learning portal connecting users to online educational activities about cancer immunotherapy with opportunities for continuing education credits. Start with Introduction to Immunology lead by Christian Capitini, MD (University of Wisconsin).
SITC members who purchase Cancer Immunotherapy Principles and Practice receive a 20 percent discount and free shipping with a promo code.*
*Available only when ordering from Demos Medical Publishing. Cannot be combined with any other offers.
Learn and share information in the SITC Cancer Immunotherapy CONNECT Open Forum! Create a free SITC CONNECT account in a few minutes, upload a profile photo and then join the conversation.
In partnership with Medscape Oncology, SITC offers a robust online learning portal designed to provide clinical oncologists with free, CME-/CE-certified education in the immunotherapy field.
Explore resources and educational opportunities for cancer
patients and those who advocate for them.
Track the latest advancements and educational opportunities in
cancer immunotherapy and immunology.
Advance science, submit your
manuscript and monitor the global progress of cancer immunotherapy research.
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Regarding lymphatic endothelial cell-related cancer and post-transplant recipients. Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) evades immune killing of tumor cells by relying on its immunomodulatory viral antigens. Organ donors in high seroprevalence ...
There is likely an unpublished cohort of patients throughout the world who were treated with ipilimumab prior to the introduction of nivolumab/ipilimumab combination and achieved an either complete remission or partial remission. These patients then ...
Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.
An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.
It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org